Advertisement
News
Advertisement

FDA to review Biodel diabetes drug candidate

Mon, 03/01/2010 - 8:17am
The Associated Press

Biodel Inc. said Monday the Food and Drug Administration will review the biotechnology company's diabetes drug candidate VIAject.

VIAject is a type of human insulin designed to be absorbed into the blood faster than currently marketed rapid-acting insulin.

The company expects the FDA to make a regulatory decision on Oct. 30.

Shares of Biodel jumped 26 cents, or 6.5 percent, to $4.25 in afternoon trading. The stock has traded between $3.22 and $6.02 over the last 52 weeks.

Advertisement
Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading